Table 2 Patient characteristics at time of CMR*

Age (mean ± SD)

83 ± 6

83 ± 7

83 ± 5

0.82

NYHA class (mean ± SD)

3.5 ± 0.8

3.4 ± 0.9

3.7 ± 0.7

0.37

ΔNYHA class since TAVR (median[IQR])

1 (0, 1)

1 (−1, 1)

0 (0, 1)

0.77

STS-PROM (%; mean ± SD)

7.8 ± 4.6

6.3 ± 2.3

9.0 ± 5.7

0.16

ΔSTS-PROM since TAVR (%; median[IQR])

0 (−0.5, 1.7)

0 (−1.1, 0)

0.8 (−0.4, 3.0)

0.15

Laboratory

Creatinine (mg/dl; median[IQR])

1.29 (1.00, 1.84)

1.11 (1.00, 1.37)

1.61 (1.06, 2.63)

0.011

ΔCreatinine since TAVR (mg/dl; median[IQR])

0.1 (−0.06, 0.39)

0.03 (−0.08, 0.19)

0.36 (0.10, 0.55)

0.13

BNP (pg/ml; median[IQR]))

496 (252, 1335)

432 (235, 546)

1038 (339, 1948)

0.05

ΔBNP since TAVR (pg/ml; median[IQR])

0 (−419, 199)

0 (−411, 85)

68 (−441, 240)

0.73

Echocardiography

Circumferential extent (%; mean ± SD)

34.2 ± 18.4

23.3 ± 18.2

44.3 ± 11.9

0.003

CMR

Ejection fraction (%; mean ± SD)

48 ± 12

47 ± 10

49 ± 14

0.78

Other valve disease greater than mild†

14 (61)

4 (36)

10 (83)

0.04